Role of ChREBP in hepatic steatosis and insulin resistance.
about
Pathophysiological role of host microbiota in the development of obesityO-GlcNAcylation and the Metabolic Shift in High-Proliferating Cells: All the Evidence Suggests that Sugars Dictate the Flux of Lipid Biogenesis in Tumor ProcessesEpigenetic mechanisms underlying the link between non-alcoholic fatty liver diseases and nutritionLiver steatosis in hepatitis C patientsCurcumin prevents high fat diet induced insulin resistance and obesity via attenuating lipogenesis in liver and inflammatory pathway in adipocytesImpact of the gut microbiota on rodent models of human diseaseLipogenesis in arterial wall and vascular smooth muscular cells: regulation and abnormalities in insulin-resistance.Identification of MicroRNAs that control lipid droplet formation and growth in hepatocytes via high-content screening.High glucose-induced O-GlcNAcylated carbohydrate response element-binding protein (ChREBP) mediates mesangial cell lipogenesis and fibrosis: the possible role in the development of diabetic nephropathyMolecular pathways in non-alcoholic fatty liver disease.High-fat diet leads to tissue-specific changes reflecting risk factors for diseases in DBA/2J mice.Differing endoplasmic reticulum stress response to excess lipogenesis versus lipid oversupply in relation to hepatic steatosis and insulin resistance.Transcriptional repressor E4-binding protein 4 (E4BP4) regulates metabolic hormone fibroblast growth factor 21 (FGF21) during circadian cycles and feeding.Metabolism and proliferation share common regulatory pathways in cancer cells.Short-term periodic consumption of multiprobiotic from childhood improves insulin sensitivity, prevents development of non-alcoholic fatty liver disease and adiposity in adult rats with glutamate-induced obesity.Altered fatty acid metabolism-related gene expression in liver from morbidly obese women with non-alcoholic fatty liver disease.Menhaden oil decreases high-fat diet-induced markers of hepatic damage, steatosis, inflammation, and fibrosis in obese Ldlr-/- mice.Treatment with ginger ameliorates fructose-induced Fatty liver and hypertriglyceridemia in rats: modulation of the hepatic carbohydrate response element-binding protein-mediated pathway.Spirulina versicolor improves insulin sensitivity and attenuates hyperglycemia-mediated oxidative stress in fructose-fed rats.Effect of transgenic extrahepatic expression of betaine-homocysteine methyltransferase on alcohol or homocysteine-induced fatty liver.Carbohydrate response element binding protein gene expression is positively regulated by thyroid hormone.Effects of low-carbohydrate diet therapy in overweight subjects with autoimmune thyroiditis: possible synergism with ChREBP.Role of nonalcoholic fatty liver disease in the development of insulin resistance and diabetes.Metabolism and secretory function of white adipose tissue: effect of dietary fat.Contribution of anthocyanin-rich foods in obesity control through gut microbiota interactions.Inhibiting CB1 receptors improves lipogenesis in an in vitro non-alcoholic fatty liver disease model.Insulin resistance, steatosis and hepatitis C virus.Impact of amino acid substitutions in hepatitis C virus genotype 1b core region on liver steatosis and glucose tolerance in non-cirrhotic patients without overt diabetes.Lxralpha deficiency hampers the hepatic adaptive response to fasting in mice.Carbohydrate-response-element-binding protein (ChREBP) and not the liver X receptor α (LXRα) mediates elevated hepatic lipogenic gene expression in a mouse model of glycogen storage disease type 1.Hepatocellular glycogenotic foci after combined intraportal pancreatic islet transplantation and knockout of the carbohydrate responsive element binding protein in diabetic mice.Triglyceride Metabolism in the Liver.Liver X receptors regulate de novo lipogenesis in a tissue-specific manner in C57BL/6 female mice.Daidzein supplementation prevents non-alcoholic fatty liver disease through alternation of hepatic gene expression profiles and adipocyte metabolism.[Cell cycle regulators CDK4 and E2F1 control glucose and lipid homeostasis].Curcumin, Cardiometabolic Health and Dementia
P2860
Q26750893-F3FB9B56-BE98-41AA-8961-78EF575BE0D3Q26770270-5765F069-0519-4B6D-8EE5-8A6CCD913FAAQ26822513-27CF94B3-75D9-4663-AEAC-8ADB8F463446Q27010631-D3F5BA2F-E27D-4FE7-8F13-E6F096CB5F55Q27311242-6A0AA88F-D8A2-434A-80AD-B8A6653F59A4Q28087215-E9731573-5DC7-4522-BB6F-AAC74235A750Q33587148-73452AA5-45B2-4094-A3BF-1ED65D461B5CQ33635237-1B337FCB-E2E9-49B5-972D-86CF6D604194Q33676739-F0C07D5F-7349-4383-A77D-5414D86FA7C2Q33890230-7C36E241-14B1-4CEC-912D-D771DEF5E5C0Q33924894-96773FDF-E8F6-49A9-805B-AB19EC2939AAQ34166238-612D9749-DFEC-4668-8406-D120F57C6C09Q34299026-A8DE6468-FF56-4FED-BA53-A3517106C915Q34419460-38E28652-7B51-4444-B99F-A973B717472FQ34469086-46C9BE58-5DD3-49B2-B713-3F03F92F1DB4Q34834198-EA704E42-035C-4F06-9115-D7986C2A61D6Q36096333-082B6574-AC85-419A-A317-2F8EDD0A4BD2Q36411221-1391E11B-F21D-4721-88B3-1234B0E4E24AQ36722401-903FACF6-8BF2-4147-9283-C677EAED6EE1Q37001200-BEA49CB0-FC31-42D6-8724-B154E7879386Q37244695-BC1D5777-6E74-4642-AE5B-30546224B5C5Q37265667-C8444759-3CD1-4883-8675-05710A798773Q37345849-2B4AC45B-27AE-4AF7-9C86-063B9685C6CCQ37590183-F0868CFC-FDBF-496B-831D-EE7A7213C33AQ38786198-B48802A4-4695-4107-856C-F3222996D696Q38939502-6E68C626-0141-4D21-AA22-209166609C54Q39240971-053CD75A-8635-487C-AFA8-C51AF5F8F65CQ43001302-37F59AA6-0285-4AF4-9DE2-9644AC21648EQ44987000-19582F43-D4DE-48E1-8BE9-D88E7E6441C0Q45558516-716658F3-CD98-45F2-879B-3282EC70A773Q47270010-32F5191D-92A2-4138-972E-EDFF932FA174Q47719467-18A96D0D-B9CB-4CF3-A5C6-6A1BC3A1B5C9Q51471193-87D5F2FF-D7B0-443F-91F4-8378D66DD650Q51612396-EDBE03DA-5CAD-441E-BCDA-D7C692BE6466Q52842515-5349543D-04CB-4CD2-B34F-FF52FE4F4C2FQ58699640-C0FC8278-F594-44CF-9C0D-D4B773F66FA5
P2860
Role of ChREBP in hepatic steatosis and insulin resistance.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Role of ChREBP in hepatic steatosis and insulin resistance.
@en
type
label
Role of ChREBP in hepatic steatosis and insulin resistance.
@en
prefLabel
Role of ChREBP in hepatic steatosis and insulin resistance.
@en
P2860
P50
P1433
P1476
Role of ChREBP in hepatic steatosis and insulin resistance
@en
P2093
Jean Girard
P2860
P356
10.1016/J.FEBSLET.2007.07.084
P407
P577
2007-08-14T00:00:00Z